Shibeikang's Clinical Study Results of Becondogrel Presented at ACC 2026 and Published in JACC, a Leading International Cardiovascular Journal

In April 2026, the clinical study results of sbk002 (Becondogrel), a next-generation antiplatelet agent independently developed by Chengdu Shibeikang Biomedical Technology Co., Ltd. (hereinafter referred to as "Shibeikang"), were presented and served as a basis for academic exchange at the 75th Annual Scientific Session of the American College of Cardiology (ACC.26). The study abstract, titled "PK/PD CHARACTERISTICS OF BECONDOGREL IN HEALTHY SUBJECTS WITH DIFFERENT CYP2C19 METABOLIC GENOTYPES,” was simultaneously published in the Journal of the American College of Cardiology (JACC).

ACC Annual Session: A Global Benchmark in Cardiovascular Academia
The ACC Annual Scientific Session is internationally recognized as a premier academic conference in in the field of cardiovascular disease. The 75th ACC Annual Session was held from March 28 to 30, 2026, under the theme "Transforming Cardiovascular Care for All." The event brought together more than 23,000 cardiovascular experts, researchers, and industry representatives from over 140 countries worldwide. The becondogrel study results were successfully selected for presentation and academic exchange at the conference.

JACC: A Leading International Journal in the Cardiovascular Field
JACC, the flagship journal of the American College of Cardiology, is ranked in Q1 among cardiovascular journals worldwide. With an impact factor of 22.3 (2024), JACC is widely recognized as a leading journal in the global cardiovascular field. The journal focuses on publishing high-quality, highly innovative original clinical and translational research findings, serving as a core source of literature guiding global clinical cardiovascular practice, research innovation, and guideline development. The study results of becondogrel were published in the April 7, 2026 issue of JACC (Volume 87, Number 13_Supplement).

Currently, Shibeikang is steadily advancing the clinical application and global strategic development of becondogrel, aiming to provide a new treatment option for patients with cardiovascular disease.

JACC《PK/PD CHARACTERISTICS OF BECONDOGREL IN HEALTHY SUBJECTS WITH DIFFERENT CYP2C19 METABOLIC GENOTYPES》